



HAL
open science

Associations of Baseline Use of Biologic or Targeted Synthetic DMARDs with COVID-19 Severity in Rheumatoid Arthritis: Results from the COVID-19 Global Rheumatology Alliance Physician Registry

Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Milena A Gianfrancesco, Zara Izadi, Kimme L Hyrich, Anja Strangfeld, Laure Gossec, Loreto Carmona, Elsa F Mateus, et al.

► To cite this version:

Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Milena A Gianfrancesco, Zara Izadi, et al.. Associations of Baseline Use of Biologic or Targeted Synthetic DMARDs with COVID-19 Severity in Rheumatoid Arthritis: Results from the COVID-19 Global Rheumatology Alliance Physician Registry. *Annals of the Rheumatic Diseases*, 2021, 80 (9), pp.1137–1146. 10.1136/annrheumdis-2021-220418 . hal-03895851

HAL Id: hal-03895851

<https://hal.sorbonne-universite.fr/hal-03895851>

Submitted on 30 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance Physician Registry

Jeffrey A Sparks MD MSc^{1*}, Zachary S Wallace MD MSc^{2*}, Andrea M Seet MPH³, Milena A Gianfrancesco MPH PhD³, Zara Izadi MPharm MAS^{3, 4}, Kimme L Hyrich MD PhD⁵, Anja Strangfeld MD PhD⁶, Laure Gossec MD PhD⁷, Loreto Carmona MD PhD⁸, Elsa F Mateus PhD⁹, Saskia Lawson-Tovey BA¹⁰, Laura Trupin MPH³, Stephanie Rush BA³, Patricia Katz PhD³, Gabriela Schmajuk MD MS^{3, 11}, Lindsay Jacobsohn BA³, Leanna Wise MD¹³, Emily L Gilbert MD PhD¹⁴, Ali Duarte-Garcia MD MSc¹⁵, Maria O Valenzuela-Almada MD¹⁶, Guillermo Pons-Estel MD, MSc, PhD¹⁷, Carolina A. Isnardi MD¹⁷, Guillermo A. Berbotto MD¹⁸, Tiffany Y-T Hsu MD PhD¹, Kristin M D'Silva MD², Naomi J Patel MD², Lianne Kearsley-Fleet PhD¹⁹, Martin Schaefer PhD⁶, Sandra Lúcia Euzébio Ribeiro MSc PhD²⁰, Samar Al Emadi MBBS FRCPC FACR¹², Liselotte Tidblad MD²¹, Carlo Alberto Scirè MD PhD²², Bernd Raffeiner MD PhD²³, Thierry Thomas MD²⁴, René-Marc Flipo MD PhD²⁵, Jérôme Avouac MD PhD²⁶, Raphaële Seror MD PhD²⁷, Miguel Bernardes MD PhD²⁸, Maria Margarida Cunha MD²⁹, Rebecca Hasseli MD³⁰, Hendrik Schulze-Koops MD PhD³¹, Ulf Müller-Ladner³⁰, Christof Specker MD³², Viviane Angelina de Souza MD³³, Licia Maria Henrique da Mota MD³⁴, Ana Paula Monteiro Gomides MD³⁵, Philippe Dieude MD PhD³⁶, Elena Nikiphorou MD PhD³⁷, Vanessa L Kronzer MD MSCI¹⁶, Namrata Singh MD MSCI³⁸, Manuel F Ugarte-Gil MD, MSc³⁹, Beth Wallace MD MSc⁴⁰, Akpabio Akpabio MD FMCP⁴¹, Ranjeny Thomas MBBS MD⁴², Suleman Bhana MD FACR⁴³, Wendy Costello⁴⁴, Rebecca Grainger MBChB BMedSci PhD⁴⁵, Jonathan S Hausmann MD⁴⁶, Jean W Liew MD MS⁴⁷, Emily Sirotych BSc⁴⁸, Paul Sufka MD⁴⁹, Philip C Robinson MBChB PhD⁵⁰, Pedro M Machado MD PhD⁵¹, Jinoos Yazdany MD MPH³, on behalf of the COVID-19 Global Rheumatology Alliance

*Contributed equally.

¹ Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

² Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

³ Division of Rheumatology, Department of Medicine, University of California, San Francisco

⁴ Department of Epidemiology and Biostatistics, University of California, San Francisco

⁵ Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

⁶ German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany

- 1
2
3 7 Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé
4 Publique, Paris France; Pitié-Salpêtrière hospital, AP-HP.Sorbonne Université,
5 Rheumatology department, Paris, France
6
7 8 Instituto de Salud Musculoesquelética, Madrid, Spain
8
9 9 Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal;
10 European League Against Rheumatism (EULAR) Standing Committee of People with
11 Arthritis/Rheumatism in Europe (PARE), Kilchberg, Switzerland
12
13 10 Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal
14 Research, University of Manchester, Manchester, United Kingdom; National Institute of
15 Health Research Manchester Biomedical Research Centre, Manchester University NHS
16 Foundation Trust, Manchester Academic Health Science Centre, Manchester, United
17 Kingdom
18
19 11 San Francisco VA Healthcare System, San Francisco
20
21 12 Rheumatology Department, Hamad Medical Corporation, Doha -Qatar
22
23 13 Division of Rheumatology, Department of Internal Medicine, University of Southern
24 California, Los Angeles, CA
25
26 14 Division of Rheumatology, Mayo Clinic, Jacksonville, Florida
27
28 15 Division of Rheumatology and Robert D. and Patricia E. Kern Center for the Science
29 of Health Care Delivery, Mayo Clinic, Rochester, Minnesota
30
31 16 Division of Rheumatology, Mayo Clinic, Rochester, Minnesota
32
33 17 SAR-COVID, Argentine Society of Rheumatology, Argentina
34
35 18 Sanatorio Británico Rosario, Chief of the Rheumatology Service
36
37 19 Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester
38 Academic Health Science Centre, Manchester, UK
39
40 20 Hospital Universitário Getúlio Vargas, Faculty of Medicine, Federal University of
41 Amazonas,Brazil
42
43 21 Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska
44 Institutet, Stockholm, Sweden
45
46 22 Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy
47
48 23 Department of Rheumatology, Central Hospital of Bolzano, Italy
49
50 24 Société Française de Rhumatologie (SFR), Department of Rheumatology, Hôpital
51 Nord, Université de Lyon-Université Jean Monnet, Saint-Etienne, France
52
53 25 Department of Rheumatology, University of Lille, Lille, France
54
55 26 Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris,
56 France
57
58 27 Department of Rheumatology, Université Paris-Saclay, Assistance Publique,
59 Hôpitaux de Paris, France
60
61 28 Department of Medicine, Faculty of Medicine, University of Porto; Rheumatology
62 Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
63
64 29 Rheumatology Department, Hospital Garcia de Orta, Almada
65
66 30 Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-
67 Liebig-University Giessen, Germany
68
69 31 Division of Rheumatology and Clinical Immunology, Department of Internal Medicine
70 IV, Ludwig-Maximilians-University Munich, Munich, Germany
71
72 32 KEM Kliniken Essen-Mitte, Department of Rheumatology and Clinical Immunology,
73 Essen-Mitte, Germany

- 1
2
3 33 Universidade Federal de Juiz de Fora (UFJF), Brazil
4 34 Hospital Universitário de Brasília, Universidade de Brasília (HUB-UnB-EBSERH),
5 Brasília-DF, Brazil
6 35 Centro Universitário de Brasília (UniCEUB), Brazil
7 36 Paris University, INSERM 1152; Bichat Claude-Bernard hospital, AP-HP, Paris
8 University, Rheumatology department, Paris, France
9 37 Centre for Rheumatic Diseases, King's College London, London, UK & Rheumatology
10 Department, King's College Hospital, London, UK
11 38 Division of Rheumatology, University of Washington, WA, USA
12 39 School of Medicine, Universidad Científica del Sur, Lima, Peru and Rheumatology
13 Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru
14 40 Department of Internal Medicine/Rheumatology, University of Michigan, VA Ann Arbor
15 Healthcare System Center for Clinical Management Research
16 41 Rheumatology Department, Royal Hallamshire Hospital, Sheffield, UK.
17 42 UQ Diamantina Institute, University of Queensland, Brisbane, Qld, Australia
18 43 Crystal Run Health, Middletown, NY, USA
19 44 Irish Children's Arthritis Network (iCAN)
20 45 Department of Medicine, University of Otago, Wellington, New Zealand
21 46 Program in Rheumatology, Boston Children's Hospital; Division of Rheumatology and
22 Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School,
23 Boston, MA, USA.
24 47 Section of Rheumatology, Department of Medicine, Boston University School of
25 Medicine, Boston, MA
26 48 Department of Health Research Methods, Evidence, and Impact, McMaster
27 University, Hamilton, ON, Canada, and Canadian Arthritis Patient Alliance, Toronto, ON,
28 Canada
29 49 Healthpartners, St. Paul, MN, USA
30 50 University of Queensland Faculty of Medicine, Brisbane, Australia
31 Royal Brisbane & Women's Hospital, Metro North Hospital & Health Service,
32 Queensland, Australia
33 51 Centre for Rheumatology & Department of Neuromuscular Diseases, University
34 College London, London, UK; National Institute for Health Research (NIHR) University
35 College London Hospitals Biomedical Research Centre, University College London
36 Hospitals NHS Foundation Trust, London, UK; Department of Rheumatology, Northwick
37 Park Hospital, London North West University Healthcare NHS Trust, London, UK
38
39
40
41
42
43
44

45 **Keywords:** COVID-19, rheumatoid arthritis, DMARDs, biologics
46
47
48
49
50

51 Manuscript word count: 2,849 (max 3,000)

52 Abstract word count: 226 (max 250)

53
54 References: 31

55
56 Tables/Figures: 4
57
58
59
60

Corresponding Authors:

Jeffrey A. Sparks, MD, MMSc

Division of Rheumatology, Inflammation, and Immunity

Brigham and Women's Hospital

60 Fenwood Road, #6016U

Boston, MA 02115

617-525-1040

jsparks@bwh.harvard.edu

@jeffsparks

Zachary S. Wallace, MD, MSc

Clinical Epidemiology Program

Division of Rheumatology, Allergy, and Immunology

Massachusetts General Hospital

100 Cambridge Street, 16th Floor

Boston, MA 02114

617-724-2507

zswallace@mgh.harvard.edu

@zach_wallace_md

ABSTRACT

Objective: To investigate baseline use of biologic or targeted synthetic (b/ts) DMARDs and COVID-19 outcomes in rheumatoid arthritis (RA).

Methods: We analyzed the COVID-19 Global Rheumatology Alliance physician registry (24/Mar/2020 to 12/Apr/2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin-6 inhibitors (IL6i), or tumor necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was: 1) no hospitalization, 2) hospitalization without oxygen, 3) hospitalization with oxygen/ventilation, or 4) death. We used ordinal logistic regression to estimate ORs (odds of being one level higher on the ordinal outcome) for each drug class compared to TNFi, adjusting for potential baseline confounders.

Results: Of 2,869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were n=237 on ABA, n=364 on RTX, n=317 on IL6i, n=563 on JAKi, and n=1,388 on TNFi. Overall, 613 (21%) were hospitalized and 157 (5.5%) died. RTX (OR 4.15, 95%CI 3.16-5.44) and JAKi (OR 2.06, 95%CI 1.60-2.65) were each associated with worse COVID-19 severity compared to TNFi. There were no associations of ABA or IL6i with COVID-19 severity.

Conclusions: People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk-mitigation strategies for these patients.

KEY MESSAGES

What is already known about this subject?

- A previous international registry study in the COVID-19 Global Rheumatology Alliance (C19-GRA) suggested that people with systemic rheumatic diseases on biologic or targeted synthetic (b/ts) DMARDs had lower odds of hospitalisation than those not using DMARDs
- Previous studies reported that people with systemic rheumatic diseases using rituximab had higher odds of COVID-19-related mortality than those using alternative DMARDs such as methotrexate.

What does this study add?

- Using the C19-GRA, we analyzed people with RA using b/tsDMARD (to limit the potential for confounding) at time of COVID-19 onset and investigated an ordinal outcome that encompassed a range of COVID-19 outcomes
- People with RA using rituximab or Janus kinase (JAK) inhibitors at COVID-19 onset were more likely to experience poor COVID-19 outcomes, ranging from hospitalisation to death, compared to tumor necrosis factor inhibitor use

How might this impact on clinical practice or future developments?

- People using rituximab or JAK inhibitors for RA are more likely to experience poor COVID-19 outcomes and should be prioritized for risk mitigation strategies.

INTRODUCTION

The ongoing Coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on patients with rheumatoid arthritis (RA), many of whom are treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs)(1). While b/tsDMARDs are important for controlling RA disease activity, their influence on COVID-19 outcomes in patients with RA remains unclear. This uncertainty has led to anxiety, social isolation due to shielding practices, and b/tsDMARDs discontinuation which may contribute to RA flares(2-4). Addressing the knowledge gaps around the influence of b/tsDMARDs on COVID-19 outcomes is a priority for people with RA and their providers.

The impact of b/tsDMARDs on COVID-19 outcomes is of particular interest since some of these medications, such as tocilizumab and baricitinib, have been studied as repurposed treatments for COVID-19. Some evidence suggests that baseline use of certain b/tsDMARDs, like tumor necrosis factor inhibitors (TNFi), for inflammatory disorders may be associated with less severe COVID-19 outcomes(5). In addition, among patients with COVID-19, treatment with interleukin (IL)-6 inhibitors and baricitinib lead to improved outcomes in some clinical trials(6-9). However, there are also concerns that baseline use of certain b/tsDMARDs, such as rituximab or abatacept, may be associated with worse COVID-19 outcomes due to impaired viral immune defenses(10, 11).

Due to sample size limitations, previous studies of b/tsDMARD use and COVID-19 outcomes have combined heterogeneous rheumatic diseases and medications and/or investigated a single outcome, such as hospitalization(5, 12). Therefore, we used

1
2
3 the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry to evaluate
4 the associations of different classes of b/tsDMARDs with a range of COVID-19
5 outcomes in people with RA.
6
7
8
9

10 11 12 **METHODS**

13 14 15 *Data source and study sample assembly*

16
17
18
19 People with rheumatic disease and COVID-19 from the C-19 GRA registry and
20 European Alliance of Associations for Rheumatology (EULAR) COVID-19 database
21 were included in the analyses. We included cases entered between March 24, 2020 and
22 April 12, 2021. The C19-GRA and EULAR databases include people with rheumatic
23 diseases diagnosed with COVID-19, as reported by rheumatology providers via two
24 international data entry portals. The details of these registries have been previously
25 reported(5, 12-17). We analyzed people with RA on b/tsDMARD at time of COVID-19
26 clinical onset. As of April 12, 2021, a total of 15,127 people with rheumatic diseases and
27 COVID-19 were reported. We included people with RA who were taking one of the
28 following medication classes: anti-CTLA4Ig (abatacept), anti-CD20 (rituximab), IL-6
29 inhibitors (tocilizumab, sarilumab), Janus kinase inhibitors (JAKi: tofacitinib, baricitinib,
30 or upadacitinib), or tumour necrosis factor inhibitors (TNFi: infliximab, etanercept,
31 adalimumab, certolizumab pegol, golimumab). The drug class of b/tsDMARD was
32 collected, rather than individual drugs. We did not include IL-1 inhibitors since these
33 were infrequently used for RA (n=4). Prior studies using the C19-GRA and EULAR
34 databases have included some patients also reported in this study, but the analyses
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 included in this study and observations reported are novel. In addition, follow-up for this
4
5 study is more current than previous publications using these data.
6
7

8
9 Data quality was assessed by the University of California, San Francisco and the
10
11 University of Manchester, UK, who both confirmed that there were no duplicates in the
12
13 data entries. Due to the de-identified and non-interventional nature of the study, it was
14
15 determined to be exempt by each institutional review board.
16
17

18 19 *Baseline b/tsDMARD exposures*

20
21
22 The exposure of interest was baseline use of a b/tsDMARD at the time of
23
24 COVID-19 clinical onset. As in previous C19-GRA investigations, we included confirmed
25
26 and presumptive cases of COVID-19 (5, 12, 14). We limited this analysis to users of
27
28 abatacept, rituximab, IL-6i, JAKi, or TNFi to limit the cohort to patients with similar RA
29
30 disease severity and minimize the impact of confounding by indication. We included
31
32 b/tsDMARD users regardless of whether they also used a csDMARD or glucocorticoids
33
34 but did not include people on conventional synthetic DMARDs (csDMARDs, e.g.,
35
36 hydroxychloroquine, methotrexate, sulfasalazine, leflunomide) monotherapy, as
37
38 monotherapy may indicate less severe RA or be due to care access barriers or
39
40 socioeconomic factors. TNFi users were the reference group since TNFi are the most
41
42 frequently used b/tsDMARD in RA. Patients with RA who were reported to be on more
43
44 than one b/tsDMARD were excluded from the analysis (n=3).
45
46
47
48
49

50 51 *COVID-19 outcomes*

52
53 The primary outcome of interest was a mutually exclusive ordinal COVID-19
54
55 severity outcome: 1) no hospitalization, 2) hospitalization with no oxygenation, 3)
56
57

1
2
3 hospitalization with any oxygenation or mechanical ventilation, and 4) death. We chose
4
5 this primary outcome to estimate the association of b/tsDMARD exposure with general
6
7 odds of worse COVID-19 severity rather than a single outcome. A similar outcome was
8
9 developed by the World Health Organization (WHO) to capture the spectrum of disease
10
11 and is used in clinical trials evaluating COVID-19 therapeutics (18). If a patient met
12
13 multiple levels of the outcome, they were only included in the highest level. At the time
14
15 of analysis, all patients were required to have a resolved clinical course.
16
17
18
19

20 *Covariates*

21
22
23 Details regarding demographics, including age, race/ethnicity, continent, and
24
25 patient characteristics, including obesity, smoking, comorbidities (interstitial lung
26
27 disease [ILD], history of cancer, hypertension, cardiovascular disease, chronic kidney
28
29 disease/end-stage kidney disease, diabetes, non-ILD pulmonary disease), RA disease
30
31 activity (as judged by the reporting physician), glucocorticoid dose for RA at the time of
32
33 COVID-19 onset, and concomitant csDMARD (methotrexate, sulfasalazine,
34
35 hydroxychloroquine) use were by physician report. For glucocorticoid dose, the amount
36
37 of prednisone-equivalent glucocorticoid prescribed was treated as a categorical variable
38
39 (none, >0 to 5 mg/day, >5 to 9 mg/day, and ≥ 10 mg/day). Hypertension and
40
41 cardiovascular disease were collapsed as a single comorbidity due to collinearity.
42
43
44
45
46

47 *Statistical analysis*

48
49
50 We reported baseline characteristics and outcomes across the exposure
51
52 categories of baseline b/tsDMARD use with descriptive statistics.
53
54
55
56
57
58
59
60

Ordinal logistic regression models were used to assess the association between each b/tsDMARD compared to TNF inhibitor use and the severity of COVID-19 on an ordinal scale in unadjusted and multivariable analyses to estimate odds ratios (OR) and 95% confidence intervals (CIs). The effect size of the ordinal outcome can be interpreted as the odds of being one level higher on the ordinal COVID-19 severity scale than the reference group. We assessed the proportional odds assumption for the ordinal regression model using the Brant test (19). Models in which the proportional odds assumption was not met, were re-fitted using the partial proportional odds model which relaxes the assumption of proportionality for offending predictors (20). We considered potential confounders known to be associated with either b/tsDMARD use or COVID-19 severity. Covariates included in multivariable models included sociodemographic features (age, sex), obesity, smoking status (ever vs. never), concomitant csDMARD use (MTX, HCQ, SSZ, or LEF), categorical glucocorticoid use/dose, categorical comorbidity count (0, 1, ≥ 2 of the following: chronic kidney insufficiency/end-stage kidney disease, diabetes, non-ILD pulmonary disease), other key comorbidities as individual variables (hypertension/cardiovascular disease, ILD, and cancer), disease activity (moderate/high vs. remission/low), continent (Europe, North America, South America, other), and calendar time (January-June 15, 2020 vs. June 16, 2020-April 12, 2021) (21). These time periods were selected based on the initial publication of the RECOVERY trial which reported a survival benefit associated with dexamethasone and influenced subsequent practice. We assumed that missing data were “missing at random.” We then performed multiple imputation five times to get pooled estimates to impute missing values for disease activity, race/ethnicity, glucocorticoid dose, smoking,

1
2
3 hypertension/cardiovascular disease, and comorbidity count. After imputation, we
4
5 compared the distribution of imputed values to the distribution of variables before
6
7 imputation to confirm that distributions were similar before and after imputation.
8
9

10
11 To confirm the robustness of our findings, we performed several sensitivity
12
13 analyses. First, we excluded patients with ILD or cancer from the analysis since
14
15 rituximab is commonly used in these patients, who may also be susceptible to poor
16
17 COVID-19 outcomes. Second, given data showing a strong association between
18
19 race/ethnicity and COVID-19 outcomes in the United States, we performed an analysis
20
21 adjusting for this variable among U.S. patients in the registry. The race/ethnicity variable
22
23 was categorized as White, Black, Hispanic, Asian, or Other/Mixed Race. However, for
24
25 the model with IL-6 inhibitors, there were few outcomes within the race/ethnicity variable
26
27 so we were unable to perform the model. Third, we used propensity score matching to
28
29 further address potential confounding by indication. We estimated propensity scores for
30
31 b/tsDMARD use based on age, sex, obesity, smoking, concomitant csDMARDs,
32
33 glucocorticoid use/dose, number of comorbidities, disease activity, region, and calendar
34
35 time. Covariate balance between each b/tsDMARD drug class and TNFi was assessed
36
37 using Love plots (**Supplemental Figures 1-4**) which showed that most of the covariates
38
39 were matched with an absolute standardized mean difference less than 0.1, denoting
40
41 sufficient matching performance (22). Ordinal logistic regression was then performed
42
43 after matching. Fourth, we repeated our primary analysis after excluding patients with a
44
45 presumptive diagnosis of COVID-19. Presumptive cases were those that lacked one of
46
47 the following: positive polymerase chain reaction (PCR) or antigen test for SARS-CoV-
48
49 2, or typical chest imaging findings. Fifth, we repeated the analysis but stratified by
50
51
52
53
54
55
56
57
58
59
60

1
2
3 calendar time (before or after June 15, 2020 when RECOVERY trials results were
4 announced) and by continent (North America or Europe) in case calendar time and
5 geography may have influenced the results. Sixth, we used a revised version of the
6 ordinal COVID-19 severity outcome that considered mechanical ventilation as its own
7 category.
8
9

10
11
12 We then repeated our primary analyses using dichotomized outcomes rather
13 than the ordinal COVID-19 severity scale to investigate whether there were particular
14 outcomes driving the associations we observed. For example, we investigated whether
15 each b/tsDMARD was associated with hospitalization (yes/no) compared to TNFi use.
16
17

18
19
20 We used the Brant test to assess whether the observed deviations from the
21 ordinal logistic regression are larger than what could be attributed to chance alone. If
22 the p-values are greater than the alpha level of 0.05, then the covariates satisfy the
23 proportional odds assumption. This assumption states that the estimate between each
24 pair of outcomes across the response levels regardless of the partition that we consider.
25 For abatacept and JAK inhibitors, both age and glucocorticoid dose violated the
26 assumption and for IL-6 inhibitors and rituximab, age, gender, and glucocorticoid dose
27 violated the assumption. In order to address the lack of proportionality for these
28 covariates, partial proportional odds models were run to relax this assumption for the
29 respective covariates for each medication category (**Supplemental Table 1**). We found
30 that the estimates were similar when comparing the proportional odds models and the
31 non-proportional odds model, so we reported the model without relaxing the
32 assumption.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results were considered statistically significant at two-sided $p < 0.05$. Analyses were conducted in R version 4.0.2.

RESULTS

Study sample and baseline characteristics

From a total of 6,132 RA cases reported to the registry, we identified 2,869 who were on abatacept ($n=237$), rituximab ($n=364$), IL-6i ($n=317$), JAKi ($n=563$), or TNFi ($n=1,388$), at time of clinical COVID-19 onset. Baseline clinical characteristics are shown in **Table 1**. The sample was predominantly female (80.8%) and mean age was 56.7 years (SD 13.4). Most patients were from Europe (51.8%) or North America (35.0%). Overall, 354 (12.3%) were obese, 582 (20.3%) were ever smokers, 810 (28.2%) were on glucocorticoids, 1,409 (49.1%) were on concomitant csDMARDs, and 510 (17.8%) had moderate/high RA disease activity. Among b/tsDMARD users, rituximab users were more likely than TNFi users to have ILD (11.0% vs. 1.4%) or a history of cancer (7.4% vs. 0.9%); JAKi users were slightly more likely than TNFi users to be obese (15.1% vs. 10.3%).

COVID-19 outcomes

Outcomes according to the COVID-19 severity scale are shown in **Table 2**. The majority of patients (78.6%) were not hospitalized, 137 (4.8%) were hospitalized without oxygenation, 319 (11.1%) were hospitalized with any oxygen or ventilation requirement, and 157 (5.5%) died. Among rituximab users, 80 (22.0%) required hospitalization with

1
2
3 any oxygen or ventilation and 54 (14.8%) died compared to 103 (7.4%) and 36 (2.6%)
4
5 TNFi users, respectively. Among JAKi users, 86 (15.3%) were hospitalized with
6
7 oxygen/ventilation and 40 (7.1%) died. Only 9 (2.8%) patients on baseline IL-6i died.
8
9

10 11 *Associations of b/tsDMARDs with COVID-19 severity*

12
13
14 The multivariable ordinal logistic regression model is shown in **Table 3**.
15
16 Compared to TNFi users, rituximab users had a 4.15 (95%CI 3.40, 3.80) greater odds of
17
18 worse COVID-19 severity as compared to patients taking TNFi, while JAKi users had a
19
20 2.06 (95%CI 1.60, 2.65) greater odds of worse COVID-19 severity. No significant
21
22 associations were found with respect to abatacept or IL-6i compared to TNFi in the
23
24 primary analysis.
25
26
27

28 29 *Sensitivity analyses*

30
31
32 Sensitivity analyses of the drug class comparisons are shown in **Table 3**. After
33
34 excluding patients with ILD or cancer, the association between rituximab with poor
35
36 COVID-19 outcomes when compared to TNFi use remained strong (OR 4.34 [95%CI
37
38 3.23, 5.82]). Among RA patients in the US, results were also similar when additionally
39
40 adjusting for race/ethnicity. We also performed a propensity score matched analysis
41
42 instead of multivariable ordinal logistic regression. The sample for each propensity
43
44 score-matched analysis is illustrated in **Supplemental Figure 5**. Rituximab users (OR
45
46 3.36 [95%CI 2.11, 5.34]) and JAKi users (OR 1.56, 95%CI 1.01, 2.42) had increased
47
48 COVID-19 severity compared to TNFi users in this analysis. In the propensity score-
49
50 matched analysis, abatacept had an OR of 1.60 (95%CI 1.02, 2.51) for the ordinal
51
52 COVID-19 severity outcome compared to TNFi. IL-6 inhibitor use was not associated
53
54
55
56
57
58
59
60

1
2
3 with COVID-19 severity in any of the analyses. Brant tests indicated that the
4
5 proportional odds assumption did not hold for propensity score models; therefore, partial
6
7 proportional odds models were used and confirmed that the effect estimates remained
8
9 consistent (data not shown).
10
11

12
13 When stratified by calendar time (before or after June 15, 2020) and restricted to
14
15 Europe or North America, results were similar (**Supplementary Table 2**).
16
17

18 19 *Individual COVID-19 outcomes*

20
21
22 We also performed analyses for each binary level of the COVID-19 severity scale
23
24 (**Table 4**). Rituximab and JAKi use were each associated with an increased odds for
25
26 each COVID-19 outcome compared to TNFi use. For example, rituximab use had
27
28 increased odds for hospitalization (OR 4.53, 95%CI 3.32, 6.18) as well as death (OR
29
30 4.57, 95%CI 3.32, 9.01) compared to TNFi use. JAKi use was associated with all
31
32 outcomes considered, including hospitalization requiring any oxygen or ventilation or
33
34 death (OR 1.55, 95%CI 1.04, 2.18) and death (OR 2.04, 95%CI 1.58, 2.65) compared to
35
36 TNFi. In these analyses, there were no statistically significant associations between
37
38 abatacept or IL-6i use and the dichotomized outcomes when compared to TNFi use.
39
40
41
42
43

44 We considered a revised version of the ordinal outcome that included mechanical
45
46 ventilation as a separate level. There were relatively few patients who survived after
47
48 requiring mechanical ventilation (**Supplementary Table 3**). Results were similar using
49
50 this revised ordinal outcome (**Supplementary Tables 4-5**).
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Among RA patients on b/tsDMARDs at the onset of COVID-19, rituximab and JAKi users were at increased odds for worse COVID-19 outcomes compared to TNFi users. In contrast, we did not find an association between abatacept or IL-6i use with worse COVID-19 outcomes when compared to TNFi users. These observations can inform decision making for providers and patients during the ongoing COVID-19 pandemic. Given the association between rituximab and JAKi use with poor outcomes, vaccination and public health measures such as mask wearing and social distancing for COVID-19 risk mitigation remain paramount. In addition, other specific interventions (e.g., monoclonal antibody treatment) might be considered in this patients with COVID-19 exposure or early infection (23).

Our observations, which use the largest sample of individuals with RA and COVID-19 assembled to date, regarding rituximab exposure confirm findings from prior studies suggesting an association between baseline use of B cell depleting therapies and worse COVID-19 outcomes in people with rheumatic diseases(12, 24, 25) and multiple sclerosis (26). We also expand upon prior observations using the C19-GRA and EULAR databases by evaluating the association of rituximab with COVID-19 severity rather than only mortality and by using an alternative reference group (TNFi rather than methotrexate) and performing propensity score analyses to further address confounding by indication. By focusing on a single disease, we also were able to identify a novel association of JAK inhibitors with COVID-19 severity. Mechanistically, the impact of B cell depletion on antibody production would be expected to impair the immune system's normal response to a viral infection. Indeed, the antibody response to

1
2
3 COVID-19 is critical for controlling the initial infection and preventing re-infection (27).
4
5 We lacked details regarding the timing of rituximab exposure in relation to the COVID-
6
7 19 infection or the duration of B cell depletion at the time of infection which may be
8
9 particularly relevant when considering the risk of a poor outcome following rituximab
10
11 exposure. It is also possible that glucocorticoids given as a pre-medication to rituximab
12
13 infusions may have contributed to the increased risk of poor COVID-19 outcomes in RA
14
15 patients on rituximab. While the results were robust to several sensitivity analyses, it is
16
17 possible that the result could be confounded by factors such as unrecognized ILD.
18
19
20
21
22

23 Our findings are of particular interest given recent clinical trials and observational
24
25 studies suggesting that IL-6i (6-8, 28-31) and JAKi (9) may improve outcomes for
26
27 patients in the general population with COVID-19. We found no association of baseline
28
29 IL-6i use in RA with COVID-19 severity compared to TNFi use. In contrast, while
30
31 baricitinib treatment may have some benefit on time to recovery for patients with more
32
33 severe COVID-19(9), we observed worse outcomes associated with baseline use of
34
35 JAKi. This was also suggested in a recent population-based study investigating RA and
36
37 other inflammatory joint diseases in Sweden (24). Glucocorticoids are known to have
38
39 benefits when initiated for moderate-to-severe COVID-19 but are also associated with
40
41 worse outcomes among those on baseline glucocorticoids at the time of infection (5,
42
43 12), though this may be explained by residual disease activity (32). Therefore, the
44
45 timing of JAKi use relative to the COVID-19 disease course may explain our findings.
46
47
48 Similar to glucocorticoids, baseline use of JAKi at time of SARS-CoV-2 infection may
49
50 enhance viral reproduction and dampen a healthy immune response while JAKi
51
52 initiation at clinical deterioration may dampen an aberrant systemic inflammatory
53
54
55
56
57
58
59
60

1
2
3 response. Alternatively, there may be relevant differences in COVID-19 outcomes
4 depending on the type of JAKi used given that JAK inhibitors like tofacitinib, baricitinib,
5 and upadacitinib target different JAKs. We were unable to perform analyses of each
6 individual JAKi since these were collected as a class. While the primary analysis found
7 no association of abatacept with COVID-19 severity, there was a statistical association
8 in the propensity score-matched analysis. Further research is needed on the safety of
9 abatacept for infection risk and severity since its mechanism of action may impair
10 adaptive immune response.
11
12
13
14
15
16
17
18
19
20
21

22
23 Our study has a number of strengths including the international nature of the
24 registry and large sample size. Additionally, we used an active comparator (TNFi),
25 which was also a b/tsDMARD in a single rheumatic disease, as well as two different
26 modeling approaches (multivariable logistic regression and propensity score matching)
27 among other sensitivity analyses to account for confounding by indication and to confirm
28 the robustness of our findings. Our observations expand upon prior general population
29 and RA cohort studies that identified older age, greater comorbidity burden, and other
30 factors associated with worse COVID-19 and must also be considered when assessing
31 an individual's risk.
32
33
34
35
36
37
38
39
40
41
42
43

44 Our study also has certain limitations. First, the GRA and EULAR registries are
45 voluntary and require a provider to submit the details of a case, perhaps biasing our
46 sample towards more severe cases. As such, the proportion of events reported across
47 exposure groups may be an overestimate of that observed among all patients with RA
48 in real world practice and should be interpreted in that context. However, the effect size
49 estimates do have clinical interpretation in potentially identifying RA patients who could
50
51
52
53
54
55
56
57
58
59
60

1
2
3 be susceptible to poor COVID-19 outcomes. While we designed the study to limit the
4 potential impact of selection bias and confounding by indication by examining advanced
5 therapies in a single rheumatic disease, it is possible that selective reporting could have
6 varied according across different b/tsDMARD classes as the exposure of interest. This
7 potential bias may have caused an upward deflection in the effect size estimate if more
8 severe cases of a particular b/tsDMARD class were systematically reported compared
9 to others, and this could contribute to the findings that we report. We further mitigated
10 this possibility by adjusting for differences in concomitant medication use, disease
11 activity, and comorbidities as well as performing an analysis removing patients with ILD
12 or cancer. Our findings remained when we excluded presumptive cases of COVID-19.
13
14 Second, though we were able to adjust for a number of potential confounders of our
15 observed associations, there is the potential for residual unmeasured confounding.
16 Analyzing only patients on b/tsDMARD may have helped minimize some unmeasured
17 confounding related to access to care since all analyzed RA patients were able to
18 receive these targeted medications. In addition, the consistent results observed in
19 sensitivity analyses excluding patients with ILD or cancer who may be more likely to
20 receive rituximab supports the robustness of our results. However, we did not have data
21 available on RA duration or previous RA medications (e.g., previous TNFi use in
22 patients on other classes of b/tsDMARDs), which may have affected the results.
23 Medications were collected by DMARD class, so we were unable to compare individual
24 medications within the same class. However, the goal of the study was to compare
25 different biologic mechanisms of action for COVID-19 severity. Additionally, it is also
26 possible that TNFi use may protect against severe COVID-19 outcomes. Thus, these
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 results should be interpreted cautiously and additional studies are needed to confirm
4
5 our observed associations. Third, while we leveraged the largest cohort of rheumatic
6
7 disease patients with COVID-19, a somewhat small number of outcomes of interest
8
9 occurred in some subgroups which may have limited our power to detect significant
10
11 differences among abatacept users, in particular. In addition, we were unable to
12
13 investigate individual JAKi or TNFi. Finally, we did not examine medication changes
14
15 after COVID-19 onset since this occurred after baseline and may have mediated the
16
17 relationship we report. Most of the drugs have lengthy biologic effects (especially
18
19 rituximab) while JAKi have short half-lives. Some clinicians may have chosen to
20
21 continue IL-6 inhibitors after COVID-19 onset, as suggested by the American College of
22
23 Rheumatology (32). Future studies are needed to investigate the association of
24
25 medication changes with COVID-19 outcomes.
26
27
28
29
30

31
32 In conclusion, use of rituximab or JAKi, but not abatacept or IL-6i use, at the time
33
34 of COVID-19 infection was associated with worse COVID-19 outcomes compared to
35
36 TNFi among RA patients. Additional studies are warranted to confirm these
37
38 observations. Strategies are needed to improve outcomes following COVID-19 RA on
39
40 rituximab or JAK inhibitors.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. *Curr Opin Rheumatol* 2021.
2. Antony A, Connelly K, De Silva T, et al. Perspectives of Patients With Rheumatic Diseases in the Early Phase of COVID-19. *Arthritis Care Res (Hoboken)* 2020;72(9):1189-95.
3. Ma MHY, Tay SH, Cheung PPM, et al. Attitudes and Behaviors of Patients With Rheumatic Diseases During the Early Stages of the COVID-19 Outbreak. *J Rheumatol* 2021;48(1):35-9.
4. George MD, Venkatachalam S, Banerjee S, et al. Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. *J Rheumatol* 2020.
5. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020;79(7):859-66.
6. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med* 2021.
7. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med* 2021;384(1):20-30.
8. Gupta S, Wang W, Hayek SS, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. *JAMA Intern Med* 2021;181(1):41-51.

- 1
2
3 9. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized
4
5 Adults with Covid-19. *N Engl J Med* 2021;384(9):795-807.
6
- 7
8 10. Tavakolpour S, Alesaeidi S, Darvishi M, et al. A comprehensive review of rituximab
9
10 therapy in rheumatoid arthritis patients. *Clin Rheumatol* 2019;38(11):2977-94.
11
- 12
13 11. Selmi C, Ceribelli A, Naguwa SM, et al. Safety issues and concerns of new
14
15 immunomodulators in rheumatology. *Expert opinion on drug safety* 2015;14(3):389-99.
16
- 17
18 12. Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-
19
20 19-related death in people with rheumatic diseases: results from the COVID-19 Global
21
22 Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2021.
23
- 24
25 13. Robinson PC, Yazdany J, Machado PM. Global research collaboration in a
26
27 pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance.
28
29 *Curr Opin Rheumatol* 2021;33(2):111-6.
30
- 31
32 14. Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of Race and Ethnicity
33
34 With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global
35
36 Rheumatology Alliance Physician Registry. *Arthritis Rheumatol* 2021;73(3):374-80.
37
- 38
39 15. Liew JW, Bhana S, Costello W, et al. The COVID-19 Global Rheumatology Alliance:
40
41 evaluating the rapid design and implementation of an international registry against best
42
43 practice. *Rheumatology (Oxford)* 2021;60(1):353-8.
44
- 45
46 16. Wallace ZS, Bhana S, Hausmann JS, et al. The Rheumatology Community
47
48 responds to the COVID-19 pandemic: the establishment of the COVID-19 global
49
50 rheumatology alliance. *Rheumatology (Oxford)* 2020;59(6):1204-6.
51
52
53
54
55
56
57
58
59
60

17. Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. *Lancet Rheumatol* 2020;2(5):e250-e3.
18. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020;383(19):1813-1826.
19. Brant R. Assessing Proportionality in the Proportional Odds Model for Ordinal Logistic Regression. *Biometrics* 1990;46(4):1171-8.
20. Williams R. Generalized Ordered Logit/Partial Proportional Odds Models for Ordinal Dependent Variables. *The Stata Journal* 2006;6(1):58-82.
21. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *American Journal of Epidemiology* 2007;165(6):710-8.
22. Zhang Z, Kim HJ, Lonjon G, et al. Balance diagnostics after propensity score matching. *Ann Transl Med* 2019;7(1):16-.
23. Lundgren JD, Grund B, Barkauskas CE, et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. *N Engl J Med* 2021;384(10):905-14.
24. Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. *Ann Rheum Dis* 2021.
25. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study [published online ahead of print, 2021 Mar 25]. *Lancet Rheumatol*. 2021;10.1016/S2665-9913(21)00059-X.

- 1
2
3 26. Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and
4 Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Annals of neurology*
5
6 2021;89(4):780-9.
7
8
9
10 27. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of
11 SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med* 2021;384(6):533-40.
12
13
14 28. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe
15 Covid-19 Pneumonia. *N Engl J Med* 2021.
16
17
18
19 29. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients
20 Hospitalized with Covid-19. *N Engl J Med* 2020;383(24):2333-44.
21
22
23 30. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in
24 Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A
25 Randomized Clinical Trial. *JAMA Intern Med* 2021;181(1):32-40.
26
27
28
29 31. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on
30 Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized
31 Clinical Trial. *JAMA Intern Med* 2021;181(1):24-31.
32
33
34
35 32. Schäfer M, Strangfeld A, Hyrich KL, et al. Response to: 'Correspondence on
36 'Factors associated with COVID-19-related death in people with rheumatic diseases:
37 results from the COVID-19 Global Rheumatology Alliance physician reported registry'
38 by Mulhearn et al. *Ann Rheum Dis* 2021.
39
40
41
42
43
44
45
46 33. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology
47 Guidance for the Management of Rheumatic Disease in Adult Patients During the
48 COVID-19 Pandemic: Version 3. *Arthritis Rheumatol* 2021;73(2):e1-e12.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements:** We wish to thank all rheumatology providers who entered data
4 into the registry.
5
6

7
8 **Funding:** Financial support from the American College of Rheumatology (ACR) and
9 European League Against Rheumatism (EULAR).
10
11

12
13 **Disclaimer:** The views expressed here are those of the authors and participating
14 members of the COVID-19 Global Rheumatology Alliance and do not necessarily
15 represent the views of the American College of Rheumatology (ACR), the European
16 League Against Rheumatism (EULAR), the (UK) National Health Service (NHS), the
17 National Institute for Health Research (NIHR), or the (UK) Department of Health, or any
18 other organisation.
19
20
21
22
23
24
25
26

27
28 **Contributors:** JAS, ZSW, AS, MAG and JY had access to the study data, developed
29 the figures and tables, and vouch for the data and analyses. AS and MAG performed
30 the statistical analyses and contributed to data quality control, data analysis and
31 interpretation of the data. JAS, ZSW, AMS, MAG, ZI, KLH, AS, LG, LC, EFM, SL-T, LT,
32 SR, PK, GS, LJ, SAE, LW, ELG, AD-G, MOV-A, GP-E, CAI, GAB, TY-TH, KMD'S, NJP,
33 PD, EN, VLK, NS, MFU-G, BW, AA, RT, SB, WC, RG, JSH, JWJ, ES, PS, PCR, PMM,
34 JY contributed to data collection, data analysis and interpretation of the data. JAS, ZSW
35 and JY, directed the work, designed the data collection methods, contributed to data
36 collection, data analysis and interpretation of the data, and had final responsibility for
37 the decision to submit for publication. All authors contributed intellectual content during
38 the drafting and revision of the work and approved the final version to be published.
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54 **Competing interests:**
55
56
57
58
59
60

- JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. Dr. Sparks has received research support from Amgen and Bristol-Myers Squibb and performed consultancy for Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum unrelated to this work.
- ZSW reports grant support from Bristol-Myers Squibb and Principia/Sanofi and performed consultancy for Viela Bio and MedPace, outside the submitted work. His work is supported by grants from the National Institutes of Health.
- AMS has no disclosures relevant to this study.
- MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]).
- ZI has no disclosures relevant to this study.
- KLH reports she has received speaker's fees from Abbvie and grant income from BMS, UCB, and Pfizer, all unrelated to this study. KLH is also supported by the NIHR Manchester Biomedical Research Centre.
- LC has not received fees or personal grants from any laboratory, but her institute works by contract for laboratories among other institutions, such as Abbvie Spain, Eisai, Gebro Pharma, Merck Sharp & Dohme España, S.A., Novartis Farmaceutica, Pfizer, Roche Farma, Sanofi, Aventis, Astellas Pharma, Actelion Pharmaceuticals España, Grünenthal GmbH, and UCB Pharma.
- LG reports research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB. all unrelated to this study.
- SLT has no disclosures relevant to this study.
- EM reports that LPCDR received support for specific activities: grants from Abbvie, Novartis, Janssen-Cilag, Lilly Portugal, Sanofi, Grünenthal S.A., MSD, Celgene, Medac, Pharmakern, GAfPA; grants and non-financial support from Pfizer; non-financial support from Grünenthal GmbH, outside the submitted work.
- AS reports grants from a consortium of 13 companies (among them AbbVie, BMS, Celltrion,
- Fresenius Kabi, Lilly, Mylan, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis, and UCB) supporting the German RABBIT register and personal fees from lectures for AbbVie, MSD, Roche, BMS, Pfizer, outside the submitted work.
- LT has no disclosures relevant to this study.
- SR has no disclosures relevant to this study.
- GS has no disclosures relevant to this study.
- PK has no disclosures relevant to this study.
- LJ has no disclosures relevant to this study.
- SA has no disclosures relevant to this study.
- LW has no disclosures relevant to this study.
- ELG has no disclosures relevant to this study.
- MOVA has no disclosures relevant to this study.

- AD has no disclosures relevant to this study. His work is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation
- TYT has no disclosures relevant to this study.
- KMD is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258) and Rheumatology Research Foundation.
- NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258)
- Lianne Kearsley-Fleet reports no disclosures relevant to this study.
- Martin Schaefer has no disclosures relevant to this study.
- Sandra Lucia Euzebio Ribeiro has no disclosures relevant to this study
- Samar Al-Emadi has no disclosures relevant to this study
- Liselotte Tidblad has no disclosures relevant to this study.
- Carlo Alberto Scirè has no disclosures relevant to this study.
- Bernd Raffeiner has no disclosures relevant to this study.
- Thierry Thomas has no disclosures relevant to this study
- René-Marc Flipo has no disclosures relevant to this study
- Jérôme Avouac received honorarium from Pfizer, BMS, Sanofi, Roche, Novartis, Abbvie, Galapagos, Fresenius kabi, Nordic Pharma, Chugai, MSD not related to this study
- Raphaelae Seror received honorarium from GSK, BMS, Fresenius Kabi, Boehringer, Jansen, Amgen, Pfizer, Roche not related to this study
- Miguel Bernardes received honorarium from Lilly, Janssen and Abbvie not related to this study
- Maria Margarida Cunha has no disclosures relevant to this study
- Rebecca Hasseli has no disclosures relevant to this study
- Hendrik Schulze-Koops has no disclosures relevant to this study
- Ulf Müller-Ladner has no disclosures relevant to this study
- Christof Specker has no disclosures relevant to this study
- Viviane Angelina de Souza has no disclosures relevant to this study.
- LMHM has received personal or institutional support from Abbvie, Janssen, Pfizer, UCB, Lilly and Roche; has delivered speeches at events related to this work and sponsored by Abbvie, Janssen, Pfizer, Roche, UCB, Sandoz, Angem, Boehringer - Ingelheim.
- Ana Paula Monteiro Gomides has no disclosures relevant to this study.
- PD has received research support from Bristol-Myers Squibb, Chugai, Pfizer and performed consultancy for Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Sanofi, Pfizer, Chugai, Roche, Janssen unrelated to this work.
- EN has no disclosures relevant to this study.
- VK has no disclosures relevant to this study.
- NS is supported by the RRF Investigator Award and the American Heart Association.
- MUG reports grant support from Janssen and Pfizer.
- BW has no disclosures relevant to this study.
- AA has no disclosures relevant to this study.
- RT has no disclosures relevant to this study.

- SB reports no competing interests related to this work. He reports non-branded consulting fees for AbbVie, Horizon, Novartis, and Pfizer (all <\$10,000).
- WC has no disclosures relevant to this study.
- RG reports no competing interests related to this work. Outside of this work she reports personal and/or speaking fees from Abbvie, Janssen, Novartis, Pfizer, Cornerstones and travel assistance from Pfizer (all < \$10,000).
- JSH reports no competing interests related to this work. He is supported by grants from the Rheumatology Research Foundation and has salary support from the Childhood Arthritis and Rheumatology Research Alliance. He has performed consulting for Novartis, Sobi, Biogen, all unrelated to this work (<\$10,000).
- JWL has received research funding from Pfizer outside the submitted work.
- ES is a Board Member of the Canadian Arthritis Patient Alliance, a patient run, volunteer-based organization whose activities are largely supported by independent grants from pharmaceutical companies.
- PS reports no competing interests related to this work. He reports honorarium for doing social media for American College of Rheumatology journals (<\$10,000).
- PMM has received consulting/speaker's fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB, all unrelated to this study (all < \$10,000). PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).
- PCR reports no competing interests related to this work. Outside of this work he reports personal consulting and/or speaking fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche (all < \$10,000).
- JY reports no competing interests related to this work. Her work is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155). Outside of this work, she has performed consulting for Eli Lilly, Pfizer, Aurinia and AstraZeneca.
- CAI, as a member of the SAR-COVID Registry received grants from Pfizer, Abbvie and Elea Phoenix during the conduct of the study. Outside of this work she reports speaking fees from Bristol-Myers Squibb.
- GPE, as a member of the SAR-COVID Registry received grants from Pfizer, Abbvie and Elea Phoenix during the conduct of the study. Outside of this work he reports personal consulting and/or speaking fees from Pfizer, GSK, Janssen and Sanofi (all < \$10,000).
- GAB, as a member of the SAR-COVID Registry received grants from Pfizer, Abbvie and Elea Phoenix during the conduct of the study. Outside of this work he reports personal consulting and/or speaking fees from Pfizer, Janssen, Eli Lilly and Bago (all < \$10,000).

Patient consent for publication: Not required.

1
2
3 **Ethics approval:** The C19-GRA physician-reported registry was determined “not
4 human subjects’ research” by the UK Health Research Authority and the University of
5 Manchester, as well as under United States Federal Guidelines assessed by the
6 University of California San Francisco Institutional Review Board.
7
8
9
10
11

12 **Data availability statement:** Data are available upon reasonable request. Applications
13 to access the data should be made to the C19-GRA Steering Committee.
14
15
16

17 **Patient and Public Involvement:** Patients were involved in the study related to
18 standing members of the C19-GRA Steering Committee and included as co-authors.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics according to use of biologic or targeted synthetic disease-modifying antirheumatic drug for rheumatoid arthritis at time of COVID-19 onset.

	Overall n=2869	Abatacept n=237	Rituximab n=364	IL-6 inhibitors n=317	JAK inhibitors n=563	TNF inhibitors n=1388
Demographics						
Mean age (years), SD	56.7, 13.4	61.4, 14.0	58.0, 12.9	56.4, 12.0	58.0, 12.3	55.2, 14.0
Female	2316 (80.8%)	188 (79.3%)	299 (82.1%)	257 (81.3%)	470 (83.5%)	1102 (79.4%)
Race/ethnicity						
White	1670 (69.0%)	78 (69.5%)	187 (64.5%)	169 (67.9%)	360 (73.2%)	829 (69.3%)
Black	113 (4.7%)	5 (3.2%)	14 (4.8%)	11 (4.4%)	22 (4.5%)	60 (5.0%)
Hispanic	472 (19.5%)	32 (20.8%)	66 (22.8%)	46 (18.5%)	79 (16.1%)	233 (19.5%)
East Asian	81 (3.3%)	8 (5.2%)	10 (3.4%)	12 (4.8%)	10 (2.0%)	37 (3.1%)
Other	85 (3.3%)	2 (1.3%)	13 (4.5%)	11 (4.4%)	21 (4.3%)	38 (3.2%)
Continent						
Europe	1486 (51.8%)	103 (43.5%)	218 (59.9%)	183 (57.7%)	283 (50.3%)	699 (50.4%)
North America	1005 (35.0%)	105 (44.3%)	111 (30.5%)	83 (26.2%)	208 (36.9%)	498 (35.9%)
South America	276 (9.6%)	20 (8.4%)	23 (6.3%)	33 (10.4%)	55 (9.8%)	145 (10.4%)
Other	302 (10.5%)	9 (3.8%)	12 (3.3%)	18 (5.7%)	17 (3.0%)	46 (3.3%)
Comorbidity count*						
0	1494 (52.1%)	113 (47.7%)	161 (44.2%)	161 (50.8%)	270 (48.0%)	789 (56.8%)
1	837 (29.2%)	70 (29.5%)	119 (32.7%)	99 (31.2%)	176 (31.3%)	373 (26.9%)

2	538 (18.8%)	54 (22.8%)	84 (23.1%)	57 (18.0%)	117 (20.8%)	226 (16.3%)
Individual comorbidities						
Hypertension	983 (34.3%)	91 (38.4%)	121 (33.2%)	108 (34.1%)	221 (39.3%)	442 (31.8%)
Cardiovascular Disease	247 (8.6%)	29 (12.2%)	36 (9.9%)	32 (10.1%)	51 (9.1%)	99 (7.1%)
Diabetes	356 (12.5%)	30 (12.8%)	54 (14.9%)	43 (13.6%)	74 (13.2%)	155 (11.3%)
Chronic kidney disease	98 (3.4%)	11 (4.7%)	11 (3.0%)	14 (4.4%)	22 (3.9%)	40 (2.9%)
Lung disease [^]	432 (15.2%)	41 (17.4%)	87 (24.0%)	44 (13.9%)	92 (16.4%)	168 (12.3%)
Interstitial lung disease	103 (3.6%)	15 (6.3%)	40 (11.0%)	15 (4.7%)	13 (2.3%)	20 (1.4%)
Cancer	40 (1.5%)	5 (2.5%)	27 (7.4%)	6 (2.2%)	5 (1.0%)	11 (0.9%)
Obesity	354 (12.3%)	31 (13.1%)	52 (14.3%)	43 (13.6%)	85 (15.1%)	143 (10.3%)
Smoking status						
Ever	582 (20.3%)	104 (43.9%)	70 (19.2%)	57 (18.0%)	99 (17.6%)	300 (21.6%)
Never	1369 (47.7%)	56 (23.6%)	142 (39.0%)	152 (47.9%)	262 (46.5%)	694 (50.0%)
Missing	918 (32.0%)	77 (32.5%)	137 (37.6%)	107 (33.8%)	202 (35.9%)	394 (28.4%)
Concomitant RA medications						
Any conventional synthetic DMARD	1409 (49.1%)	118 (49.8%)	194 (53.3%)	102 (32.2%)	228 (40.5%)	767 (55.3%)
Methotrexate	1188 (41.4%)	92 (38.8%)	146 (40.1%)	91 (28.7%)	188 (33.4%)	671 (48.3%)
Sulfasalazine	136 (4.7%)	9 (3.8%)	26 (7.1%)	8 (2.5%)	18 (3.2%)	75 (5.4%)
Hydroxychloroquine	260 (9.1%)	25 (10.5%)	58 (15.9%)	18 (5.7%)	43 (7.6%)	116 (8.4%)
Leflunomide	176 (10.5%)	26 (11.0%)	49 (13.5%)	20 (6.3%)	29 (5.2%)	117 (8.4%)
Glucocorticoid dose (median, IQR)	5.0 (4.0, 6.0)	5.0 (4.0, 5.5)	5.0 (5.0, 7.5)	5.0 (4.5, 7.0)	5.0 (3.0, 5.0)	5.0 (5.0, 7.0)
Categorical glucocorticoid use/dose						
No glucocorticoid use	1756 (61.2%)	120 (56.9%)	186 (51.1%)	173 (54.6%)	320 (63.5%)	957 (76.1%)

Glucocorticoid >0 to 5 mg/day prednisone equivalent	600 (20.9%)	68 (32.2%)	93 (25.5%)	69 (21.8%)	149 (29.6%)	221 (17.6%)
Glucocorticoid 6-9 mg/day prednisone equivalent	68 (2.4%)	8 (3.8%)	10 (2.7%)	15 (4.7%)	12 (2.4%)	23 (1.8%)
Glucocorticoid ≥10 mg/day prednisone equivalent	142 (4.9%)	15 (7.1%)	28 (7.7%)	19 (6.0%)	23 (4.6%)	57 (4.5%)
Missing	303 (10.6%)	26 (11.0%)	47 (12.9%)	41 (12.9%)	59 (10.5%)	130 (9.4%)
RA disease activity						
Remission or low	1,949 (67.9%)	147 (74.2%)	226 (76.1%)	198 (77.3%)	388 (78.7%)	990 (81.5%)
Moderate or high	510 (17.8%)	51 (25.8%)	71 (23.9%)	58 (22.7%)	105 (21.3%)	225 (18.5%)
Missing	410 (14.3%)	39 (16.5%)	67 (18.4%)	61 (19.2%)	70 (12.4%)	173 (12.5%)
Confirmed COVID-19	2333 (81.3%)	201 (84.8%)	304 (83.5%)	244 (77.0%)	475 (84.4%)	1109 (79.9%)

n (%) presented unless otherwise specified.

*Comorbidity count included diabetes, lung disease, and chronic kidney disease.

^Interstitial lung disease, chronic obstructive pulmonary disease, asthma, or other lung disease.

COVID-19, Coronavirus Disease 2019; DMARDs, disease-modifying antirheumatic drugs; IL-6, interleukin-6; JAK, Janus kinase; RA, rheumatoid arthritis; SD, standard deviation, TNF, tumor necrosis factor, HCQ, hydroxychloroquine

Table 2. Frequencies and proportions of outcomes in the ordinal COVID-19 severity scale according to baseline use of biologic or targeted synthetic disease-modifying antirheumatic drug for patients with rheumatoid arthritis at time of COVID-19 onset (n=2,869).

COVID-19 severity scale	Overall n=2869	Abatacept n=237	Rituximab n=364	IL-6 inhibitors n=317	JAK inhibitors n=563	TNF inhibitors n=1388
1) Not hospitalized	2256 (78.6%)	181 (76.4%)	210 (57.7%)	271 (85.5%)	409 (72.6%)	1185 (85.4%)
2) Hospitalized without oxygenation	137 (4.8%)	12 (5.1%)	20 (5.5%)	13 (4.1%)	28 (5.0%)	64 (4.6%)
3) Hospitalized with any oxygen or ventilation	319 (11.1%)	26 (11.0%)	80 (22.0%)	24 (7.6%)	86 (15.3%)	103 (7.4%)
4) Death	157 (5.5%)	18 (7.6%)	54 (14.8%)	9 (2.8%)	40 (7.1%)	36 (2.6%)

COVID-19, Coronavirus Disease 2019; IL-6, interleukin-6; JAK, Janus kinase; TNF, tumor necrosis factor.

Table 3. Results of primary and sensitivity analyses investigating the associations of baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs with COVID-19 severity (n=2,869).

	Abatacept		Rituximab		IL-6 inhibitors		JAK inhibitors		TNF inhibitor s
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	Ref
Unadjusted	1.88 (1.35, 2.63)	<0.01	4.63 (3.60, 5.96)	<0.01	1.00 (0.71, 1.41)	0.99	2.28 (1.80, 2.88)	<0.01	Ref
Age- and sex-adjusted	1.40 (0.99, 1.99)	0.06	4.45 (3.43, 5.77)	<0.01	1.06 (0.68, 1.37)	0.84	2.10 (1.64, 2.68)	<0.01	Ref
Multivariable adjusted (primary analysis)	1.26 (0.88, 1.80)	0.21	4.15 (3.16, 5.44)	<0.01	0.81 (0.56, 1.18)	0.55	2.06 (1.60, 2.65)	<0.01	Ref
Confirmed cases only*	1.14 (0.77, 1.68)	0.52	4.25 (3.17, 5.69)	<0.01	0.74 (0.49, 1.11)	0.15	2.05 (1.57, 2.69)	<0.01	Ref
Excluding patients with ILD or cancer**	1.18 (0.79, 1.76)	0.43	4.34 (3.23, 5.82)	<0.01	0.81 (0.54, 1.21)	0.30	2.14 (1.64, 2.79)	<0.01	Ref
Restricted to US and additionally adjusted for race***	1.16 (0.79, 1.69)	0.45	4.77 (3.57, 6.38)	<0.01**	†	†	2.86 (1.76, 4.65)	<0.01*	Ref
Propensity score matched****	1.60 (1.02, 2.51)	0.04	4.70 (3.31, 6.65)	<0.01	0.76 (0.46, 1.23)	0.26	2.09 (1.50, 2.90)	<0.01	Ref

The effect size is the odds of being one level higher on the ordinal COVID-19 severity scale than the reference group (TNF inhibitor users).

Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

*n=2,333 in the analysis analyzing only confirmed COVID-19 cases.

**n= 2,704 in the analysis excluding ILD and cancer.

***n=868 in the US-only analysis.

1
2
3 ****n for each pair of propensity-score matched analyses: ABA: 236 TNF: 1376; RTX: 364 TNFi: 1382;
4 IL6i: 313 TNFi: 1387; JAKi: 560 TNFi: 1379

5 †Due to the small number of events in the covariate of race, this model could not be analyzed.
6

7 CI, confidence interval; COVID-19, Coronavirus Disease 2019; IL-6, interleukin-6; ILD, interstitial lung
8 disease; JAK, Janus kinase; OR, odds ratio; TNFi, tumor necrosis factor inhibitors.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only


Table 4. Multivariable* odds ratios of biologic or targeted synthetic disease-modifying antirheumatic drugs at each binary level of the COVID-19 severity scale (n=2,869).

COVID-19 outcome	Abatacept		Rituximab		IL-6 inhibitors		JAK inhibitors		TNF inhibitors
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	
Hospitalized	1.18 (0.76, 1.82)	0.47	4.53 (3.32, 6.18)	<0.01	0.84 (0.53, 1.33)	0.45	2.40 (1.78, 3.24)	<0.01	Ref
Hospitalized with oxygenation/ventilation or death	1.12 (0.70, 1.81)	0.63	2.87 (2.03, 4.06)	<0.01	0.72 (0.43, 1.20)	0.20	1.55 (1.04, 2.18)	0.01	Ref
Death	1.46 (0.72, 2.89)	0.30	4.57 (3.32, 9.01)	<0.01	1.13 (0.50, 2.59)	0.77	2.04 (1.58, 2.65)	<0.01	Ref
Mechanical ventilation (restricted to only hospitalized patients; n = 613)	1.41 (0.94, 2.10)	0.09	4.05 (3.08, 5.33)	<0.01	0.75 (0.51, 1.10)	0.14	2.03 (1.56, 2.62)	<0.01	Ref
Mechanical ventilation or death	1.14 (0.78, 1.66)	0.50	4.44 (3.39, 5.82)	<0.01	0.74 (0.50, 1.09)	0.12	2.02 (1.56, 2.61)	<0.01	Ref


*Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity

Supplementary Material for “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance Physician Registry” by Sparks JA, Wallace ZS, et al.

Supplementary Figure 1: Love plot for abatacept vs. TNF inhibitors.




Only


Supplementary Figure 2: Love plot for rituximab vs. TNF inhibitors.

Review Only

Supplementary Figure 3: Love plot for IL-6 inhibitors vs. TNF inhibitors.




View Only

Supplementary Figure 4: Love plot for JAK inhibitors vs. TNF inhibitors.

-view Only

Supplementary Figure 5: Flow diagram illustrating analyzed sample for propensity score matching analyses.



Review Only

Supplementary Table 1. Sensitivity analysis restricting to study period before or after June 16, 2021 and by North America or Europe.

	Abatacept		Rituximab		IL-6 inhibitors		JAK inhibitors		TNF inhibitors
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	Ref
Restricted to North America* (January 1, 2020 to June 15, 2020)	0.94 (0.40, 2.21)	0.89	3.95 (1.93, 8.06)	<0.01	0.59 (0.18, 1.93)	0.38	1.90 (1.06, 3.40)	0.03	Ref
Restricted to Europe (January 1, 2020 to June 15, 2020)	1.11 (0.55, 2.23)	0.77	5.01 (3.10, 8.09)	<0.01	1.00 (0.52, 1.92)	0.99	1.72 (1.01, 2.94)	0.05	Ref
Restricted to Europe (June 16, 2020-April 12, 2021)	1.45 (0.50, 4.23)	0.50	7.34 (3.94, 13.65)	<0.01	0.28 (0.08, 1.02)	0.05	2.61 (1.41, 4.82)	<0.01	Ref

Adjusted for age, sex, region, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

*There were too few cases to analyze North America June 16, 2020-April 12, 2021.

Supplementary Table 2. Frequencies and proportions of outcomes using a revised ordinal COVID-19 severity scale according to baseline use of biologic or targeted synthetic disease-modifying antirheumatic drug for patients with rheumatoid arthritis at time of COVID-19 onset (n=2,869).

COVID-19 severity scale	Overall n=2,869	Abatacept n=237	Rituximab n=364	IL-6 inhibitors n=317	JAK inhibitors n=563	TNF inhibitors n=1388
1) Not hospitalized	2256 (78.6%)	181 (76.4%)	210 (57.7%)	271 (85.5%)	409 (72.6%)	1185 (85.4%)
2) Hospitalized with or without oxygenation (but no mechanical ventilation)	428 (14.9%)	36 (11.0%)	91 (25.0%)	36 (11.4%)	108 (19.2%)	157 (11.3%)
3) Hospitalized with mechanical ventilation	28 (1.0%)	2 (0.8%)	9 (2.5%)	1 (0.32%)	6 (1.1%)	10 (0.7%)
4) Death	157 (5.5%)	18 (7.6%)	54 (14.8%)	9 (2.8%)	40 (7.1%)	36 (2.6%)

Supplementary Table 3. Associations of b/tsDMARD use with COVID-19 severity using a revised ordinal outcome scale.

	Abatacept		Rituximab		IL-6 inhibitors		JAK inhibitors		TNF inhibitors
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	Ref
Using different ordinal outcome scale as supplemental analysis									
Unadjusted	1.87 (1.34, 2.61)	0.25	4.50 (3.50, 5.79)	<0.01	0.99 (0.70, 1.40)	0.96	2.23 (1.76, 2.82)	<0.01	
Multivariable Adjusted	1.24 (0.78, 2.19)	0.36	3.60 (3.40, 3.80)	<0.01	0.83 (0.50, 1.37)	0.46	1.59 (1.11, 2.28)	0.01	

Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

Supplementary Table 4. Associations of b/tsDMARD use with COVID-19 severity using a revised ordinal outcome scale.

	Abatacept		Rituximab		IL-6 inhibitors		JAK inhibitors		TNF inhibitors
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	Ref
Multivariable adjusted (primary analysis)	1.24 (0.78, 2.19)	0.36	3.60 (3.40, 3.80)	<0.01	0.83 (0.50, 1.37)	0.46	1.59 (1.11, 2.28)	0.01	Ref
Excluding patients with ILD or cancer*	1.24 (0.78, 1.96)	0.36	4.15 (2.95, 5.84)	<0.01	0.66 (0.40, 1.07)	0.09	1.76 (1.25, 2.47)	<0.01	Ref
Restricted to US and additionally adjusted for race**	1.00 (0.48, 2.12)	0.99	3.82 (2.72, 5.37)	<0.01	0.66 (0.40, 1.07)	0.09	1.67 (1.19, 2.35)	<0.01	Ref
Propensity score matched***	1.72 (0.99, 2.98)	0.051	3.36 (2.11, 5.34)	<0.01	0.68 (0.35, 1.32)	0.25	1.56 (1.01, 2.42)	0.049	Ref

Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

*n= 2,704 1,563 in the analysis excluding ILD and cancer.

**n=622 868 in the US-only analysis.

***n for each pair of propensity-score matched analyses: ABA: 236 TNFi: 1376; RTX: 364 TNFi: 1382; IL6i: 313 TNFi: 1387; JAKi: 560 TNFi: 1379

1
2
3 CI, confidence interval; COVID-19, Coronavirus Disease 2019; IL-6, interleukin-6; ILD, interstitial lung
4 disease; JAK, Janus kinase; OR, odds ratio; TNFi, tumor necrosis factor inhibitors.
5
6
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only